Ursodeoxycholic acid Orion 250 mg נורווגיה - נורבגית - Statens legemiddelverk

ursodeoxycholic acid orion 250 mg

orion corporation - espoo - ursodeoksykolsyre - kapsel, hard - 250 mg

Stocrin 600 mg נורווגיה - נורבגית - Statens legemiddelverk

stocrin 600 mg

orifarm as - efavirenz - tablett, filmdrasjert - 600 mg

Clopidogrel ratiopharm האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

clopidogrel ratiopharm

teva b.v. - clopidogrel (as hydrogen sulfate) - myocardial infarction; acute coronary syndrome; peripheral vascular diseases; stroke - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. voksne pasienter som lider av akutt koronar syndrom:ikke-st-segment elevasjon akutt koronar syndrom (ustabil angina eller non-q-bølge myocardial infarction), inkludert pasienter som gjennomgår en stent plassering etter perkutan koronar intervensjon, i kombinasjon med acetylsalisylsyre (asa). st-segment elevasjon akutte myocardial infarction, i kombinasjon med asa i medisinsk behandlede pasienter kvalifisert for trombolytisk behandling. forebygging av atherothrombotic og tromboemboliske hendelser i atrial fibrillationin voksne pasienter med atrieflimmer som har minst en risikofaktor for vaskulære hendelser, er ikke egnet for behandling med vitamin k-antagonister (vka) og som har en lav risiko for blødning, clopidogrel er indisert i kombinasjon med asa for forebygging av atherothrombotic og tromboemboliske hendelser, inkludert hjerneslag.

Norvir האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

norvir

abbvie deutschland gmbh co. kg - ritonavir - hiv-infeksjoner - antivirale midler til systemisk bruk - ritonavir er angitt i kombinasjon med andre antiretrovirale midler til behandling av hiv-1-infiserte pasienter (voksne og barn fra 2 år og eldre).

Tabrecta האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karsinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Livtencity האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirusinfeksjoner - antivirale midler til systemisk bruk - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). det bør vurderes å offisielle retningslinjer for riktig bruk av antivirale midler.

Aubagio האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

aubagio

sanofi winthrop industrie - teriflunomide - multippel sklerose - selektive immunosuppressiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Teriflunomide Mylan האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - multippel sklerose, relapsing-remitting - immunsuppressive - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Teriflunomide Accord האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - multippel sklerose, relapsing-remitting - immunosuppressants, selektiv immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Clopidogrel Medical Valley 75 mg נורווגיה - נורבגית - Statens legemiddelverk

clopidogrel medical valley 75 mg

medical valley invest ab - klopidogrelbesilat - tablett, filmdrasjert - 75 mg